Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
- PMID: 9927058
Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
Abstract
The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3-restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[9(61)]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9(754)]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[9(61)] binds five of five A3 supertype molecules with high affinity, and the HER2[9(754)] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.
Similar articles
-
Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.Cancer Res. 1998 Feb 15;58(4):732-6. Cancer Res. 1998. PMID: 9485028
-
Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.Cancer Res. 2000 Sep 15;60(18):5223-7. Cancer Res. 2000. PMID: 11016651
-
Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.Br J Cancer. 2001 Jan 5;84(1):94-9. doi: 10.1054/bjoc.2000.1547. Br J Cancer. 2001. PMID: 11139320 Free PMC article.
-
New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses.Melanoma Res. 1997 Aug;7 Suppl 2:S95-8. Melanoma Res. 1997. PMID: 9578423 Review.
-
Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review.J Clin Oncol. 2002 Apr 15;20(8):2197-207. doi: 10.1200/JCO.2002.08.017. J Clin Oncol. 2002. PMID: 11956282 Review.
Cited by
-
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts.Chem Rev. 2018 Aug 22;118(16):7409-7531. doi: 10.1021/acs.chemrev.7b00678. Epub 2018 Jul 27. Chem Rev. 2018. PMID: 30052023 Free PMC article. Review.
-
Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.J Transl Med. 2010 Sep 16;8:84. doi: 10.1186/1479-5876-8-84. J Transl Med. 2010. PMID: 20843377 Free PMC article. Clinical Trial.
-
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.Cancer Immunol Immunother. 2010 Jan;59(1):161-71. doi: 10.1007/s00262-009-0738-z. Epub 2009 Jul 21. Cancer Immunol Immunother. 2010. PMID: 19621224 Free PMC article.
-
An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform.Oncoimmunology. 2012 Nov 1;1(8):1258-1270. doi: 10.4161/onci.21355. Oncoimmunology. 2012. PMID: 23243589 Free PMC article.
-
Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.Cancer Immunol Immunother. 2010 May;59(5):715-27. doi: 10.1007/s00262-009-0791-7. Epub 2009 Nov 11. Cancer Immunol Immunother. 2010. PMID: 19904532 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous